

Research and Reviews: Journal of Medical and Health Sciences

Hepatitis: Overview

Mohd Allaiddin*

Master's in Biochemistry, Bharatiya Vidya Bhavans, Osmania University, Hyderabad, India

Commentary

Received: 12/03/2015

Revised: 03/04/2015

Accepted: 24/04/2015

*For Correspondence

Mohd Allaiddin, Bharatiya Vidya Bhavans, Osmania University, Hyderabad, India

Keywords: Viral hepatitis, hepatocellular carcinoma, hepatitis C

INTRODUCTION

Viral hepatitis is the most well-known reason for interminable liver illness overall and records for around 80% of all hepatocellular carcinoma cases [1-3]. In spite of noteworthy advance in our comprehension of viral hepatitis, compelling treatment choices are still distracted for a substantial number of patients and numerous fundamental and clinical issues stay uncertain. For instance, little is thought about the cell components intervening HBV and HCV section and uncoating [4-10]. Besides, the commitment of inborn and versatile invulnerable reactions in the early period of contamination for viral freedom and perseverance is not completely caught on [11-14].

There are five fundamental causative specialists of viral hepatitis, eluded to as hepatitis infections sort A, B, C, D and E (HAV, HBV, HCV, HDV, HEV) [15-18]. These five infections are of most prominent concern due to the weight of ailment and passing [19]. As per World Health Organization (WHO) around 2 billion individuals worldwide have been contaminated with the HBV and around 350 million live with perpetual Infection [20-24]. It is assessed that 600 000 persons pass on every year because of the intense or ceaseless results of hepatitis B: liver cirrhosis and malignancy [25-28]. Besides, it is assessed that 3-4 million individuals are contaminated with the HCV every year [29,30]. 130-170 million individuals are chronically contaminated with HCV and at danger of creating liver cirrhosis and/or liver malignancy [31-35]. More than 350 000 individuals pass on from HCV-related liver sicknesses every year [36]. Factually, 60-70% of HCV chronically-contaminated persons create interminable liver malady, 5-20% create cirrhosis and 1-5% kick the bucket from cirrhosis or liver [37-40].

To address these and other imperative issues, for example, medication testing, immunomodulatory methods and HCC pathogenesis, creature models and cell based instruments are of focal significance [41-44]. A few creature models have been set up for hepatic viral infection [45]. Each of them adds to the comprehension of pathogenesis in a particular manner [46]. For instance, much has been found out about the safe reaction to mammalian hepatic viral infection and advancement of hepatocellular carcinoma in the woodchuck model, while the duck model has been broadly used for evaluating antiviral methodologies [47-52]. Concerning, the chimpanzee is the main solid creature show so far. In any case, the advancement of the replicon framework has yielded an abundance of imperative experiences in HV Virus replication and infection cell collaborations [53-56].

Viruses Causing Hepatitis

A few infections may bring about PTH: hepatitis A infection (HAY), hepatitis B infection (HBY), hepatitis delta infection (HDY), hepatitis non-A, non-B infections (HNANBy), cytomegalovirus (CMY) and Epstein-Barr Virus (EBY). 91% of all PTH cases will be instances of hepatitis non-B, and the greater part of

these (96%) are brought about by the so far unidentified HNANB infections [57-60]. Hepatitis A has a short viral stage, and contamination never prompts an interminable infection state.

Transmission through blood transfusion, albeit hypothetically conceivable if blood somehow managed to be transfused from a benefactor amid the most recent days of the brooding period, is amazingly uncommon and assumes no handy part [61-65]. There are not very many archived instances of transmission of hepatitis A through blood transfusion. In later studies, less than 10% of PTH is created by hepatitis B: Its decay to close vanishing as a reason for PTH is because of the capacity to recognize HBV bearers through the identification of HBsAg in the serum, a screening that today's tests for HBsAg have made so delicate that no HBV transporters stay undetected [66-68].

Hypothetically, transmission is conceivable if blood is given amid the breeding period when HBsAg is still not discernible but rather when the blood as of now contains little measures of irresistible HBV [69].

Pathogenesis of Hepatitis

A percentage of the particular epidemiological qualities for HV contamination include: high pervasiveness of HV disease, high rate of asymptomatic bearers, high risk of maternal-newborn child transmission, high proportion of incessant to intense infection, high hazard of developing liver cirrhosis and essential HCC, high rate of HV hereditary change and poor reaction to interferon treatment [70-73].

HV contamination is portrayed by its inclination to advance into chronicity and by a wide clinical range. Around 85% of patients contaminated by HV will create endless contamination and determination of intense hepatitis C is seen in just 15% [74-77]. The seriousness of the liver illness fluctuates generally from asymptomatic constant disease, with ordinary liver tests and almost typical liver, to serious endless hepatitis, driving quickly to cirrhosis and hepatocellular carcinoma [78-81]. The components in charge of the ingenuity of HCV contamination and for the liver sores are not surely known [82]. The absence of an effective in vitro replication framework or a creature show (the chimpanzee model is constrained) has enormously hampered the investigation of these components [83,84].

Transmission

Parenteral introduction to the hepatitis infection is the most effective method for transmission.

- Injection medication
- Blood transfusion
- Sex with an intravenous medication client
- Having been in prison over three days
- Religious scarification
- Having been hit or cut with a grisly protest
- Pierced ears or body parts
- Immunoglobulin infusion

Very frequently in patients with recently analyzed HV contamination no reasonable danger component can be recognized.

Components that may expand the danger of HV contamination incorporate more prominent quantities of sex accomplices, history of sexually transmitted maladies, and inability to utilize a condom [85-88]. Whether hidden HIV contamination builds the danger of hetero HV transmission to a uninfected accomplice is vague.

The seroprevalence of HV in MSM (men who have intercourse with men) ranges from around 4 to 8%, which is higher than the HV predominance repo

Vaccination against Hepatitis disease

Vaccine against hepatitis and is in the early phases of advancement: live lessened, inactivated entire infection and recombinant or engineered oligopeptide antibody arrangements are under study [89-92]. These antibodies will be of overall population wellbeing significance however won't impact PTH [93]. The plasma-determined HBsAg hepatitis antibody has been demonstrated to be completely protected, exceptionally viable and free of significant side responses [94-96]. Be that as it may, the immunization is not adequately immunogenic in immuno smothered people, for example, dialysis patients, and the antibody is lavish. Its source (HBsAg-containing human plasma) is restricted and will turn out to be progressively so in future [97-100]. Endeavors have been made, consequently, to plan HBsAg by sub-atomic strategies: the whole genome of HBV has been cloned, mapped and sequenced, in this way making it conceivable to recognize the genome locales coding for HBsAg [101-103]. These genome pieces can be remove of the genome, increased in plasmids in microbes, and used to deliver HBsAg in an expression framework, for example, yeast cells [104-106]. Utilization of mammalian cells as expression frameworks for the generation of HBsAg has additionally been examined: the expense and potential pollution of essential cells with different infections, and the potential neoplastic qualities of set up cell lines conveying oncogenes, make these cells by and large unsatisfactory [107-109]. Immunizations arranged in such cells may get to be adequate once methods for generation are created that reject all conceivable destructive nucleic corrosive or protein [110].

REFERENCES

1. Hassan EA, et al. The Impact of Serum Interleukin-17 on Chronic Hepatitis C and Its Sequelae. *J Liver.* 2014;3:163.
2. Ennaifer R, et al. Refractory Ascites in Cirrhosis: Prevalence and Predictive Factors. *J Liver.* 2014;3:162.
3. Dukova D and Kotzev I. Clinical Analysis of 75 Patients with Primary Biliary Cirrhosis. *J Liver.* 2014;3:161.
4. Nakamura A, et al. A Caution in the use of the NAFIC Scoring System as a Diagnostic Screening Tool for Nonalcoholic Steatohepatitis. *J Gastroint Dig Syst.* 2014; 4:221.
5. Nour E, et al. Overlap Syndrome of Primary Biliary Cirrhosis and Autoimmune Hepatitis with Unusual Initial Presentation as an Acute Hepatic Failure. *J Liver.* 2014;3:160.
6. Moore TL, et al. Polymer-Coated Hydroxyapatite Nanoparticles for the Delivery of Statins. *J Nanomed Nanotechnol.* 2014;5:237.
7. Carvalho CF, et al. Association of Doppler Wave Pattern of Hepatic Veins and Fatty Liver Disease Degree. *J Liver.* 2015;4:174.
8. Aslan A, et al. Effects of Nonalcoholic Fatty Liver Disease on the Hepatic Vein and Artery. *J Med Diagn Meth.* 2014;3:161.
9. Jia C, et al. A Novel Technique for Harvesting Hepatic Vein Blood and Time Course of Posthepatic Reactive Oxygen Species after Liver Transplantation in Rats. *J Transplant Technol Res.* 2012;S1:008.
10. Schwartz L and Coldwell D. Is Liver Disease Caused by Increased Pressure? Interstitial Pressure as a Causative Mechanism in Carcinogenesis and in the Differential Blood Supply in Liver Tumors from the Hepatic Artery. *J Liver.* 2014;3:156.
11. Janák V, et al. Embolization of Post-Traumatic Pseudoaneurysm of the Proper Hepatic Artery. *Surgery Curr Res.* 2012;2:119.
12. Albricker ACL, et al. Carotid Artery Intima-Media Thickness and Nonalcoholic Fatty Liver Disease Severity. *J Cardiovasc Dis Diagn.* 2014;2:175.
13. Ma S, et al. Gallic Acid Attenuates Dimethylnitrosamine-induced Acute Liver Injury in Mice through Nrf2-mediated Induction of Heme Oxygenase-1 and Glutathione-s-transferase Alpha 3. *Med chem.* 2014;4:663-669.

14. Kim SY, et al. The Hypolipidemic and Hypoglycemic Activities of Fermented Brown Rice Fibers by Regulating PPAR α and ChREBP in the Livers of C57BL/6J Mice. *J Nutr Food Sci.* 2014;4:307.
15. Mavila N, et al. Progenitor Cells in Liver Development, Regeneration and Repair. *Cell Dev Biol.* 2014;3:144.
16. Goh GBB, et al. Diabetes Mellitus, Insulin, Sulfonylurea and Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease. *J Diabetes Metab.* 2014;5:410.
17. Halldorson JB. The Impact of Market Forces on Liver Transplant Allocation. *Surgery Curr Res.* 2014;4:e117.
18. Goh GBB, et al. Pharmacologic Management of Non-Alcoholic Fatty Liver Disease. *Adv Pharmacoepidemiol Drug Saf.* 2014;3:157.
19. Subedi N, et al. Liver and Spleen Injuries and Associated Rib Fractures: An Autopsy Study. *J Forensic Res.* 2014;5:240.
20. Cammann S, et al. Chronic Bile Duct Stenosis after Hepaticojejunostomy Requiring Re-Operation Leading to Liver Transplantation—A Case Report. *J Gastroint Dig Syst.* 2014;4:215.
21. de Piano A, et al. Nonalcoholic Fatty Liver Disease (NAFLD), a Manifestation of the Metabolic Syndrome: New Perspectives on the Nutritional Therapy. *Endocrinol Metab Syndr.* 2014;3:135.
22. Kawabe N, et al. Is the Indication of Liver Resection for Hepatocellular Carcinoma Expanding with the Application of Laparoscopic Approach?. *J Gastroint Dig Syst.* 2014;4:214.
23. Lesmana CRA. Alcoholic Liver Disease and Alcohol in Non-Alcoholic Liver Disease: Does it Matter?. *J Metabolic Syndr.* 2014;3:147.
24. Yazbek S, et al. Hepatitis E Virus in the Countries of the Middle East and North Africa Region: An Awareness of an Infectious Threat to Blood Safety. *Clin Microbiol.* 2015;4:191.
25. Behranwala A, et al. Non-Hodgkins Lymphoma Involving Multiple Cardiac Chambers with Skeletal Muscle Involvement in a Hepatitis C Positive Patient. *J Vasc Med Surg.* 2015;3:191.
26. Wang CH, et al. Predicting Therapeutic Results of Interferon Based Treatment by Modeling the First Week Viral Kinetics in Patients with Chronic Hepatitis C. *J Gastrointest Dig Syst.* 2015;5:270.
27. Tulara NK. Concurrent Infection with Malaria, Dengue and Hepatitis A Virus together. *J Trop Dis.* 2015;3:155.
28. Zhang X, et al. Regulation of Cellular MicroRNA Expression in Oligodendrocytes during Acute and Persistent Coronavirus Infection. *Virology.* 2015;4:138.
29. Katsounas A, et al. Differential Specificity of Interferon-alpha Inducible Gene Expression in Association with Human Immunodeficiency Virus and Hepatitis C Virus Levels and Declines in vivo. *J AIDS Clin Res.* 2015;6:410.
30. Ali H, et al. Hepatitis: Prevalence, Risk Factors and Associated Co-morbidities in Local Population of Karachi, Pakistan. *J Bioequiv Availab.* 2015;7:051-055.
31. Daoud SS. Genome Wide Identification of FGFR2 Alternative Splicing in Hepatitis C: Potential Roles in Malignant transformation. *J Pharmacogenomics Pharmacoproteomics.* 2014;5: e140.
32. Deschamps F. HBV Vaccine Used. *J Vaccines Vaccin.* 2014;5:259.
33. Higgs G, et al. Using Bayesian Models to Locate Mutations for HBV Drug Resistance. *J Hematol Thrombo Dis.* 2014;2:166.
34. Chemin I, et al. Several Key Players Involved in Hepatitis-B Virus Innate Response. *Clin Microbiol.* 2014;3:174.
35. Ibrahim AA, et al. Dietary Patterns in Egyptian Patients with Chronic Hepatitis C Related Liver Disease: A Cross-Sectional Study. *J Liver.* 2015;4:176.
36. Sargin G, et al. Antiphospholipid Syndrome, Factor V Leiden Mutation and Chronic Viral Hepatitis B: A Case with Extremely Numerous Recurrent Miscarriage. *Rheumatology (Sunnyvale).* 2015;5:148.

37. Shizuma T. Liver Complications Associated with Systemic Lupus Erythematosus. *Rheumatology (Sunnyvale)*. 2015;5:146.
38. Miruka CO, et al. Design of a Recombinant Hepatitis B Vaccine Based on Stably Binding HLA-I Peptides. *J Biomol Res Ther*. 2015;4:120.
39. Ichimura M, et al. An SHR/NDmcr-cp Rat Model of Non-alcoholic Steatohepatitis with Advanced Fibrosis Induced by a High-fat, High-cholesterol Diet. *J Obes Weight Loss Ther*. 2015;5:244.
40. Salvana EMT, et al. HIV with Hepatitis B Co-Infection: Optimizing Treatment in Resource-Limited Settings. *J AIDS Clin Res*. 2015;6:425.
41. Wong SY and Hann HW. Anti-Viral Therapy can Prevent Recurrent Hepatocellular Carcinoma Associated with Hepatitis B: Recent Development. *J Antivir Antiretrovir* . 2015;7:022-025.
42. Alkhan AA. Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Infections among Hemodialysis Patients. *General Med*. 2015;3:165.
43. Qian F, et al. Switching to Telbivudine for Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients with Poor Response to Interferon-Alpha Therapy: A Two-Center Retrospective Study. *J Gastrointest Dig Syst*. 2015;5:254.
44. Nasim Z, et al. Negligence of Hepatitis C Virus Genotyping in Pakistan: Reason for the Increasing Non- Responsiveness to Interferon Therapies. *J Antivir Antiretrovir*. 2014;6:153-153.
45. Joshi RM. Hepatitis E Virus: A Renewed Hope with Hecolin. *Clin Microbiol*. 2015;4:e122.
46. Naseemuddin R and Singal AK. Liver Transplantation for Alcoholic Hepatitis: Light at the End of Tunnel. *J Liver*. 2015;4:e110.
47. Lv Y, et al. Grading of Peripheral Cytopenias due to Splenomegaly and Hepatitis B Cirrhotic Portal Hypertension. *J Hypertens*. 2014;3:182.
48. Ueda K and Omori H. Successful Generation of Hepatitis B virus (HBV) Pseudotype Particle; A Versatile Tool for Identification of the HBV Receptor and Investigation of HBV Infectivity. *J Liver*. 2015;4:169.
49. Arzenton E, et al. Acute Hepatitis Caused by Green Tea Infusion: A Case Report. *Adv Pharmacoepidemiol Drug Saf*. 2014;3:170.
50. Sobhonslidsuk A, et al. The First Case Series of Combined Liver-Kidney Transplantation (CLKT) from Thailand. *J Gastrointest Dig Syst*. 2014;4:246.
51. Oldfield EC, et al. Nonalcoholic Fatty Liver Disease and the Gut Microbiota: Exploring the Connection. *J Gastrointest Dig Syst*. 2014;4:245.
52. Zayed N, et al. Low Serum Alpha-fetoprotein Level an Important Predictor for Therapeutic Outcome in Egyptian Patients with Chronic Hepatitis C: A Data-Mining Analysis . *J Gastrointest Dig Syst*. 2014;4:240.
53. Trehanpati N, et al. Sequential Therapy with Tenofovir Plus Peg Interferon Enhances Innate and Adaptive Immunity Compared to Tenofovir Monotherapy in Chronic Hepatitis B Patients. *J Clin Cell Immunol*. 2014;5:272.
54. Okonkwo Uchenna C, et al. Effects of Silymarin on Treatment Na⁺ve Patients with Chronic Hepatitis B Infection-A Randomized Controlled Trial. *J Infect Dis Ther*. 2014;2:168.
55. Mengal MH, et al. Cross Sectional Assessment of Knowledge, Attitude and Practice towards Hepatitis C among Adolescents in Quetta, Pakistan. *Dentistry*. 2014;4:263.
56. Qureshi H, et al. Aflatoxins and Hepatitis B, C Viral Associated Hepatocarcinogenesis. *J Cell Sci Ther*. 2014;5:179.
57. Stewart A, et al. Complex Interactions of Darunavir in Patients with HIV and Multiple Comorbidities: Understanding Toxicity in Two Cases with Very Different Outcomes. *J AIDS Clin Res*. 2014;5:377.
58. Eshbaugh M and Zito S. Abatacept therapy for Rheumatoid Arthritis in patients with Hepatitis C Virus infection comorbidity: A Series of Four Patients. *Rheumatology (Sunnyvale)*. 2014;S16:007.

59. Fazlalipour M, et al. Recombinant Core ϵ 2 Protein Expressed in *Pichia pastoris* Yeast a Candidate Vaccine for Hepatitis C Virus. *J Antivir Antiretrovir*. 2014;6:139-147.
60. Kawtar I, et al. Verrucous Psoriasis and Verrucous Lichen Associated With an Autoimmune Hepatitis. *J Clin Diagn Res*. 2014;2:107.
61. Alou-El-Makarem MM, et al. Evaluation of Carbonylated Proteins in Hepatitis C Virus Patients. *Mod Chem appl*. 2014;2:130.
62. El- Ghitany EM. Need and Response to Hepatitis B Virus Booster Immunization among Egyptian Type 1 Diabetic Students 10-17 Years after Initial Immunization: A Quasi-Experimental Comparative Study. *J Vaccines Vaccin*. 2014;5:236.
63. Ignatius Irudayam J, et al. Modeling Liver Diseases Using Induced Pluripotent Stem Cell (iPSC) - Derived Hepatocytes. *J Stem Cell Res Ther*. 2014;4:218.
64. Piñero F, et al. A Case of Granulomatous Hepatitis and Pancytopenia Secondary to *Bacillus Chalmette Guerin* Immunotherapy (BCG). *Med chem*. 2014;4:531-532.
65. de Almeida TMB, et al. Evaluation of the Expression of c-MYC Protein during Liver Fibrosis Progression in Chronic Hepatitis Developed by Hepatitis C Virus Infected Patients. *J Carcinog Mutagen*. 2014;5:182.
66. Ma L. Pathology Features and Molecular Genetic Mechanisms of Hepatocellular Carcinoma Development in Patients with Hepatitis C Associated Liver Cirrhosis. *Hereditary Genet*. 2014;3:e109.
67. Lesmana CRA. Alcoholic Liver Disease and Alcohol in Non-Alcoholic Liver Disease: Does it Matter?. *J Metabolic Synd*. 2014;3:147.
68. Bigot A, et al. Body Mass Index, Fatty Liver Index and Other Metabolic Disturbances Differentially Affect Albuminuria and Glomerular Filtration Rate in the General Population. *J Diabetes Metab*. 2014;5:387.
69. Croagh CMN, et al. Therapies for Chronic Hepatitis B: Review of Indications, Outcomes and New Tools for Tailoring Treatments to Patients. *J Antivir Antiretrovir*. 2014;6:068-074.
70. Ikezaki H, et al. Efficacy and Tolerance of Interferon β Plus Ribavirin Treatment for Chronic Hepatitis C Patients with Depression or Thrombocytopenia Comparison with Pegylated Interferon α Plus Ribavirin Treatment. *J Liver*. 2014;3:155.
71. Kamkamidze G, et al. Factors Associated with Persistence of Hepatitis B Virus Infection. *J Liver*. 2014;3:153.
72. Usha K Misra, et al. Predictors of Drug Induced Hepatotoxicity in Tuberculous Meningitis. *J Neuroinfect Dis*. 2014;5:146.
73. Kumar A, et al. Identification of Novel Hepatitis C Virus NS3-4A Protease Inhibitors by Virtual Screening Approach. *J Microb Biochem Technol*. 2014;R1:005.
74. Zaheer HA, et al. Prevalence and Trends of Hepatitis B, Hepatitis C and Human Immunodeficiency Viruses among Blood Donors in Islamabad, Pakistan 2005-2013. *J Blood Disorders Transf*. 2014;5:217.
75. Savvoula S, et al. Genotype 4 Hepatitis C Virus Responds Worse than Genotype 1 to 48-Week Combination Treatment with Pegylated Interferon Alpha Plus Ribavirin: a Greek Multi-Centered Study. *J Antivir Antiretrovir*. 2013;S3:006.
76. Barnawal SP, et al. Human Immunodeficiency Virus and Hepatitis B Virus Dual Infection in Nepal. *J Infect Dis Ther*. 2014;2:142.
77. Viksna L, et al. Biochemical and Immunogenetic Diagnostic Markers Less Commonly Used for Predicting the Efficacy of Chronic Hepatitis C Etiotropic Therapy. *Virology*. 2014;3:129.
78. Shehab NG. Hepatitis C: Prevention and Management. *Nat Prod Chem Res*. 2014;2:e108.
79. Toru Shizuma. Efficacy of Treatments for Patients with Chronic Liver Disease due to Coinfection with Hepatitis B and C Viruses. *J Gastroint Dig Syst*. 2014;4:181.

80. Parvez MK and Ali R. Hepatitis E Virus Cross-Reactivity and False-Seropositivity: Challenges to Diagnosis. *J Liver*. 2014;3:e109.
81. Gouvêa AdFTB, et al. Long-Term Persistence of Hepatitis A Antibodies in Pediatric HIV-Infected Patients after Primary Immunization: Association with Immunological Profile and Response to Revaccination. *J AIDS Clin Res*. 2014;5:295.
82. Grossmann SMC, et al. Stimulated and Non-Stimulated Salivary Flows Should be Tested for the Presence of HCV RNA in Saliva Samples from Patients with Chronic Hepatitis C. *Dentistry*. 2014;4:232.
83. Noorali S, et al. Effect of Differentially Expressed MicroRNAs 602 and 323-5p on Hepatitis C Virus Genotype 1b Viral Load in Infected Liver Cells. *J Infect Dis Ther*. 2014;2:138.
84. Kishida Y, et al. Restoration of Innate Immune Responses may be a Novel Therapeutic Strategy for Treatment of Chronic Hepatitis C Virus Infection. *Biol Med*. 2014;6:196.
85. Reddy NM and Savani BN. Hepatitis B Reactivation in Patients with Hematological Malignancies and Stem Cell Transplantation. *J Blood Lymph*. 2013;4:114.
86. Zunga PM. "Entecavir in Severe Acute Hepatitis B". *J Liver*. 2014;3:149.
87. Joshi RM. Global Eradication of Hepatitis C Virus: A Herculean Task. *Clin Microbial*. 2014;3:e118.
88. Uyanikoglu A. Chronic Hepatitis B Infection. *J Infect Dis Ther*. 2014;2:133.
89. Oxenkrug GF, et al. Disturbances of Tryptophan Metabolism and Risk of Depression in HCV Patients Treated with IFN-Alpha. *J Infect Dis Ther*. 2014;2:131.
90. Ferenci P. Breakthroughs in Treatment of Chronic Hepatitis C - Time for an Obituary for Peginterferon/Ribavirin? *J Infect Dis Ther*. 2014;2:130.
91. Kouakep TY, et al. A Model for Hepatitis B with Chronological and Infection Ages. *J Appl Computat Math*. 2013;3: 148.
92. Smith JK. A Case of Pituitary Resistant Free Triiodothyronine Toxicosis Following Hepatitis B Immunization. *Intern Med*. 2014;4:142.
93. Gilmore JL, et al. Nanoimaging of ssRNA: Genome Architecture of the Hepatitis C Virus Revealed by Atomic Force Microscopy. *J Nanomed Nanotechol*. 2014;S5:010.
94. Okechukwu N, et al. The Seroprevalence of Hepatitis B Viral Infection in HIV Tested Positive Individuals in Owerri, Imo State, Nigeria. *J AIDS Clin Res*. 2014;5:273.
95. Rehman HU. Association of Obstructive Sleep Apnea Syndrome (OSAS) and Nonalcoholic Steatohepatitis (NASH). *J Clin Case Rep*. 2014;4:e124.
96. Salem EH, et al. Recurrent Hepatitis C Virus (Genotype 4) Infection after Living Donor Liver Transplantation: Risk Factors and Outcome. *J Liver*. 2014;3:148.
97. Shalmani HM, et al. Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-Related Chronic Disease. *J Liver*. 2013;3:147.
98. Qasim A. Role of Surveillance in Hepatocellular Carcinoma. *J Gastroint Dig Syst*. 2013;3:159.
99. Adeyemi AA, et al. Immunochromatographic Testing Method for Hepatitis B, C in Blood Donors. *J Antivir Antiretrovir*. 2013;S3:005.
100. Singh G, et al. Anemia in Patients with Chronic Hepatitis C Infection during Triple Therapy with Telaprevir or Boceprevir - A Controlled Study. *J Antivir Antiretrovir*. 2013;5:173-177.
101. Vassallo G, et al. Liver Transplantation for Alcoholic Liver Disease. *J Alcoholism Drug Depend* 2:143. Li S, Onder FO, Xie Q, Liu Y, Toy M (2013) Cost-effectiveness of Early Detection of Inactive and Treatment of Active Cases in a High Endemic Chronic Hepatitis B Region. *J Antivir Antiretrovir*. 2013;5:154-159.
102. Ueda K. One Year Passed Since A Bile Acid Transporter (Sodium Taurocholate Cotransporting Peptide [NTCP] Was Nominated as A Hepatitis B Virus (HBV) Entry Receptor; Has the NTCP Has Been as A Real HBV Receptor?. *J Infect Dis Ther*. 2013;1:e102.

103. Yang Y, et al. The Effect and Possible Mechanism of Double-Stranded DNA on Replication of Hepatitis B Virus. *J Mol Genet Med*. 2013;7:89.
104. Singh P, et al. Serology for Hepatitis B Virus Inhemodialysis Patients: What is Necessary? *J Vaccines Vaccin*. 2013;4:210.
105. Daoud SS. Hepatitis C Pharmacogenetics: Possible Solutions for an Existing Problem. *J Pharmacogenomics Pharmacoproteomics*. 2013;4:e135.
106. Dabiri R, et al. Detection of Undiagnosed Wilson's Disease after Hepatitis A Virus Infection. *J Liver*. 2013;2:130.
107. El-Gilany AH, et al. Prevalence of Hepatitis C Virus Antibodies among Municipal Solid Waste Collectors in Mansoura, Egypt. *Occup Med Health Aff*. 2013;1:133.
108. Abdelaali B, et al. Hepatitis C Viral Prevalence and Seroconversion in Moroccan Hemodialysis Units: Eight Year Follow Up. *J Med Diagn Meth*. 2013;2:141.
109. Susan Amirian E, et al. Preliminary Findings on the Effects of Interferon- α Treatment on Human Papilloma virus Infection in a Small Pilot Study of HIV and Hepatitis C Virus Co-Infected Men. *Epidemiol*. 2013;3:139.
110. Peluso MME, et al. Exocyclic DNA Adducts in a Murine Model of Non-alcoholic Steatohepatitis. *J Carcinog Mutagen*. 2013;S3:003.